Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Molecular mechanisms of diabetic cardiomyopathy.

Bugger H, Abel ED.

Diabetologia. 2014 Apr;57(4):660-71. doi: 10.1007/s00125-014-3171-6. Review.

2.

Sphingolipids, lipotoxic cardiomyopathy, and cardiac failure.

Park TS, Goldberg IJ.

Heart Fail Clin. 2012 Oct;8(4):633-41. doi: 10.1016/j.hfc.2012.06.003. Review.

3.

The diabetic cardiomyopathy.

Tarquini R, Lazzeri C, Pala L, Rotella CM, Gensini GF.

Acta Diabetol. 2011 Sep;48(3):173-81. doi: 10.1007/s00592-010-0180-x. Review.

PMID:
20198391
4.

Taking diabetes to heart--deregulation of myocardial lipid metabolism in diabetic cardiomyopathy.

Bayeva M, Sawicki KT, Ardehali H.

J Am Heart Assoc. 2013 Nov 25;2(6):e000433. doi: 10.1161/JAHA.113.000433. Review. No abstract available.

5.

The role of cardiac lipotoxicity in the pathogenesis of diabetic cardiomyopathy.

Ussher JR.

Expert Rev Cardiovasc Ther. 2014 Mar;12(3):345-58. doi: 10.1586/14779072.2014.891939. Review.

PMID:
24552544
6.

Autophagic adaptations in diabetic cardiomyopathy differ between type 1 and type 2 diabetes.

Kanamori H, Takemura G, Goto K, Tsujimoto A, Mikami A, Ogino A, Watanabe T, Morishita K, Okada H, Kawasaki M, Seishima M, Minatoguchi S.

Autophagy. 2015;11(7):1146-60. doi: 10.1080/15548627.2015.1051295.

7.

Role of changes in cardiac metabolism in development of diabetic cardiomyopathy.

An D, Rodrigues B.

Am J Physiol Heart Circ Physiol. 2006 Oct;291(4):H1489-506. Review.

8.

Unbreak my heart: targeting mitochondrial autophagy in diabetic cardiomyopathy.

Kubli DA, Gustafsson ÅB.

Antioxid Redox Signal. 2015 Jun 10;22(17):1527-44. doi: 10.1089/ars.2015.6322. Review.

9.

Alterations in connexin 43 during diabetic cardiomyopathy: competition of tyrosine nitration versus phosphorylation.

Joshi MS, Mihm MJ, Cook AC, Schanbacher BL, Bauer JA.

J Diabetes. 2015 Mar;7(2):250-9. doi: 10.1111/1753-0407.12164.

10.

Update on diabetic cardiomyopathy: inches forward, miles to go.

Tillquist MN, Maddox TM.

Curr Diab Rep. 2012 Jun;12(3):305-13. doi: 10.1007/s11892-012-0274-7.

PMID:
22528596
11.

Updating experimental models of diabetic cardiomyopathy.

Fuentes-Antrás J, Picatoste B, Gómez-Hernández A, Egido J, Tuñón J, Lorenzo Ó.

J Diabetes Res. 2015;2015:656795. doi: 10.1155/2015/656795. Review.

12.

Diabetes and chronic heart failure: from diabetic cardiomyopathy to therapeutic approach.

Dei Cas A, Spigoni V, Ridolfi V, Metra M.

Endocr Metab Immune Disord Drug Targets. 2013 Mar;13(1):38-50. Review.

PMID:
23369136
13.

Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes.

Severson DL.

Can J Physiol Pharmacol. 2004 Oct;82(10):813-23. Review.

PMID:
15573141
14.

Mitochondrial dysfunction in diabetic cardiomyopathy.

Duncan JG.

Biochim Biophys Acta. 2011 Jul;1813(7):1351-9. doi: 10.1016/j.bbamcr.2011.01.014. Review.

15.

The vulnerable myocardium. Diabetic cardiomyopathy.

Bugger H, Bode C.

Hamostaseologie. 2015;35(1):17-24. doi: 10.5482/HAMO-14-09-0038. Review.

PMID:
25408270
16.

Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes.

Li Y, Ma J, Zhu H, Singh M, Hill D, Greer PA, Arnold JM, Abel ED, Peng T.

Diabetes. 2011 Nov;60(11):2985-94. doi: 10.2337/db10-1333.

17.

Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission.

Wong TC, Piehler KM, Kang IA, Kadakkal A, Kellman P, Schwartzman DS, Mulukutla SR, Simon MA, Shroff SG, Kuller LH, Schelbert EB.

Eur Heart J. 2014 Mar;35(10):657-64. doi: 10.1093/eurheartj/eht193.

18.

Diazoxide preconditioning of endothelial progenitor cells from streptozotocin-induced type 1 diabetic rats improves their ability to repair diabetic cardiomyopathy.

Ali M, Mehmood A, Anjum MS, Tarrar MN, Khan SN, Riazuddin S.

Mol Cell Biochem. 2015 Dec;410(1-2):267-79. doi: 10.1007/s11010-015-2560-6.

PMID:
26359087
19.

An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy.

Palomer X, Salvadó L, Barroso E, Vázquez-Carrera M.

Int J Cardiol. 2013 Oct 9;168(4):3160-72. doi: 10.1016/j.ijcard.2013.07.150. Review.

PMID:
23932046
20.

Molecular and metabolic mechanisms of cardiac dysfunction in diabetes.

Mandavia CH, Aroor AR, Demarco VG, Sowers JR.

Life Sci. 2013 Mar 28;92(11):601-8. doi: 10.1016/j.lfs.2012.10.028. Review.

Items per page

Supplemental Content

Support Center